Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05298423
Title	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + MK-7684A + Pemetrexed Disodium Cisplatin + Durvalumab + Paclitaxel Carboplatin + MK-7684A + Paclitaxel Cisplatin + Etoposide + MK-7684A Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Etoposide
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| ITA \| ISR \| GRC \| ESP \| DEU \| CZE \| BRA \| AUS